Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...

We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change ...

Those prescribed Wegovy or Zepbound or the combination of bupropion and naltrexone also showed a tendency to drink less.

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...